Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: the MALACHITE-I/II trials

Dore, Gregory J.Conway, BrianLuo, YanJanczewska, EwaKnysz, BrygidaLiu, YanStreinu-Cercel, AdrianCaruntu, Florin AlexandruCurescu, ManuelaSkoien, RichardGhesquiere, WayneMazur, WłodzimierzSoza, AlejandroFuster, FranciscoGreenbloom, SusanMotoc, AdrianaArama, VictoriaShaw, DavidTornai, IstvánSasadeusz, JosephDalgard, OlavSullivan, DanielleLiu, XuanKapoor, MudraCampbell, AndrewPodsadecki, Thomas2019-01-112019-01-112016Journal Of Hepatology. -64 : 1 (2016), p. 19-28. -J. Hepatol. - 0168-82780168-8278http://hdl.handle.net/2437/262947Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: the MALACHITE-I/II trialsfolyóiratcikkopen access articlehttp://webpac.lib.unideb.hu:8082/ebib/CorvinaWeb?action=cclfind&resultview=long&ccltext=idno+BIBFORM076632OrvostudományokKlinikai orvostudományokhttps://linkinghub.elsevier.com/retrieve/pii/S0168827815005577http://dx.doi.org/10.1016/j.jhep.2015.08.0152019-05-2400036666570000784961817155